TARIS Biomedical is a clinical stage specialty pharmaceutical company focused on developing a pipeline of innovative treatments for bladder diseases. Current therapies for these conditions are characterized by limited efficacy and/or systemic side effects. TARIS Biomedical's delivery platform is designed to improve treatment by providing controlled, sustained delivery of drug directly to target tissues. TARIS's most advanced product candidate, LiRIS, is currently in Phase 2 clinical development for the treatment of Interstitial Cystitis.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/02/13 | $12,500,000 |
Flagship Ventures Flybridge Capital Partners Polaris Partners Third Rock Ventures | undisclosed | |
| 10/27/15 | $32,000,000 | Venture |
Flagship Ventures Polaris Partners RA Capital | undisclosed |
